Preoperative neurodevelopment of children with moyamoya angiopathy.


Journal

Developmental medicine and child neurology
ISSN: 1469-8749
Titre abrégé: Dev Med Child Neurol
Pays: England
ID NLM: 0006761

Informations de publication

Date de publication:
02 2021
Historique:
accepted: 14 09 2020
pubmed: 25 10 2020
medline: 15 4 2021
entrez: 24 10 2020
Statut: ppublish

Résumé

To preoperatively assess the neurodevelopment of a predominantly white population of children with moyamoya angiopathy (MMA). Assessments of 40 children with MMA (24 females, 16 males; mean age 6y 11mo, range 20mo-16y) included tests for non-verbal IQ and fine motor skills, and questionnaires on quality of life, behaviour, and executive functions. The Paediatric Stroke Outcome Measure (PSOM) score was evaluated by a paediatric neurologist. Children with MMA had significantly lower non-verbal IQ scores (mean IQ 92.1, SD 19.6, p=0.015) and fine motor skills (z-score -1.84, p=0.004) than population norms. Patients with posterior cerebral artery (PCA) involvement had poorer non-verbal IQ scores than those without (79.6, SD 24.6 vs 95.2, SD 17.2, p=0.042). Higher PSOM scores were related to lower non-verbal IQ scores (Spearman's rank correlation coefficient -0.43, p=0.006), while the presence of stroke, bilaterality, disease versus syndrome, and age at diagnosis had no significant effect on non-verbal IQ. Quality of life, behaviour, and executive functions were in the typically developing range. Children with MMA are more likely to manifest intellectual and fine motor skill impairment before surgical intervention. PCA involvement is an additional risk factor for lower non-verbal IQ. Children with moyamoya angiopathy have intellectual and fine motor skill impairment before surgical intervention. Posterior cerebral artery involvement and higher Paediatric Stroke Outcome Measure scores may predict poorer performance.

Identifiants

pubmed: 33098576
doi: 10.1111/dmcn.14708
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

218-225

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2020 Mac Keith Press.

Références

Smith ER, Scott RM. Moyamoya: epidemiology, presentation, and diagnosis. Neurosurg Clin N Am 2010; 21: 543-51.
Suzuki J, Takaku A. Cerebrovascular "moyamoya" disease. Disease showing abnormal net-like vessels in base of brain. Arch Neurol 1969; 20: 288-99.
Khan N, Schuknecht B, Boltshauser E, et al. Moyamoya disease and Moyamoya syndrome: experience in Europe; choice of revascularisation procedures. Acta Neurochir 2003; 145: 1061-71.
Largo RH, Pfister D, Molinari L, Kundu S, Lipp A, Duc G. Significance of prenatal, perinatal and postnatal factors in the development of AGA preterm infants at five to seven years. Dev Med Child Neurol 1989; 31: 440-56.
Kitchen L, Westmacott R, Friefeld S, et al. The pediatric stroke outcome measure: a validation and reliability study. Stroke 2012; 43: 1602-8.
Bayley N. Bayley Scales of Infant and Toddler Development Manual. San Antonio, TX: The Psychological Corporation, 2006.
Laros JA, Tellegen PJ, Wijnberg-Williams BJ. Construction and validation of the SON-R 5 1/2-17, the Snijders-Oomen non-verbal intelligence test. Groningen, the Netherlands, 1991.
Snijders JT, Snijders-Oomnen N, Laros JA, Tellegen PJ, Huijnen MAH. Snijders-Oomen Non-Verbal Intelligence Test-Revised. Lisse: Swets Test Publishers, 1985.
Petermann F, Petermann U. Wechsler Intelligence Scale for Children-Fourth Edition (WISC-IV), deutsche version. Frankfurt: Pearson Assessment, 2011.
Petermann F. Wechsler Preschool and Primary Scale of Intelligence-III (WPPSI-III), Deutsche Version. Frankfurt: Pearson Assessment, 2009.
Largo RH, Fischer JE, Rousson V. Neuromotor development from kindergarten age to adolescence: developmental course and variability. Swiss Med Wkly 2003; 133: 193-9.
Gioia GA, Isquith PK, Guy SC, Kenworthy L. The Behavior Rating Inventory of Executive Function. Odessa, FL: Psychological Asssessment Resources, 2000.
Woerner W, Becker A, Rothenberger A. Normative data and scale properties of the German parent SDQ. Eur Child Adolesc Psychiatry 2004; 13: 3-10.
Ravens-Sieberer U, Auquier P, Erhart M, et al. The KIDSCREEN-27 quality of life measure for children and adolescents: psychometric results from a cross-cultural survey in 13 European countries. Qual Life Res 2007; 16: 1347-56.
Matsushima Y, Aoyagi M, Masaoka H, Suzuki R, Ohno K. Mental outcome following encephaloduroarteriosynangiosis in children with moyamoya disease with the onset earlier than 5 years of age. Childs Nerv Syst 1990; 6: 440-3.
Imaizumi T, Hayashi K, Saito K, Osawa M, Fukuyama Y. Long-term outcomes of pediatric moyamoya disease monitored to adulthood. Pediatr Neurol 1998; 18: 321-5.
Ishii R, Takeuchi S, Ibayashi K, Tanaka R. Intelligence in children with moyamoya disease: evaluation after surgical treatments with special reference to changes in cerebral blood flow. Stroke 1984; 15: 873-7.
Lee JY, Choi YH, Cheon JE, et al. Delayed posterior circulation insufficiency in pediatric moyamoya disease. J Neurol 2014; 261: 2305-13.
Kronenburg A, van den Berg E, van Schooneveld MM, et al. Cognitive functions in children and adults with moyamoya vasculopathy: a systematic review and meta-analysis. J Stroke 2018; 20: 332-41.
Williams TS, Westmacott R, Dlamini N, et al. Intellectual ability and executive function in pediatric moyamoya vasculopathy. Dev Med Child Neurol 2012; 54: 30-7.
Hsu Y-H, Kuo M-F, Hua M-S, Yang C-C. Selective neuropsychological impairments and related clinical factors in children with moyamoya disease of the transient ischemic attack type. Childs Nerv Syst 2014; 30: 441-7.
Shim K-W, Park E-K, Kim J-S, Kim D-S. Cognitive outcome of pediatric moyamoya disease. J Korean Neurosurg Soc 2015; 57: 440-4.
Funaki T, Takahashi JC, Takagi Y, et al. Impact of posterior cerebral artery involvement on long-term clinical and social outcome of pediatric moyamoya disease. J Neurosurg Pediatr 2013; 12: 626-32.
Schaefer C, von Rhein M, Knirsch W, et al. Neurodevelopmental outcome, psychological adjustment, and quality of life in adolescents with congenital heart disease. Dev Med Child Neurol 2013; 55: 1143-9.

Auteurs

Sabina Serra (S)

Child Development Centre, University Children's Hospital, Zurich, Switzerland.

Julietta Kugler (J)

Child Development Centre, University Children's Hospital, Zurich, Switzerland.

Martina Hug (M)

Child Development Centre, University Children's Hospital, Zurich, Switzerland.
Moyamoya Centre, Department of Surgery, University Children's Hospital, Zurich, Switzerland.

Annette Hackenberg (A)

Moyamoya Centre, Department of Surgery, University Children's Hospital, Zurich, Switzerland.
Department of Paediatric Neurology, University Children's Hospital, Zurich, Switzerland.

Beatrice Latal (B)

Child Development Centre, University Children's Hospital, Zurich, Switzerland.
Moyamoya Centre, Department of Surgery, University Children's Hospital, Zurich, Switzerland.

Nadia Khan (N)

Moyamoya Centre, Department of Surgery, University Children's Hospital, Zurich, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH